LONA — LeonaBio, Inc.

Summary of Athira Pharma's Q4 2021 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $54.9 million, or $1.49 per share, for the year ended December 31, 2021, compared to a net loss of $19.9 million, or $1.67 per share, in 2020.
• Research and Development Expenses: Increased to $42.8 million from $13.3 million in 2020, driven by heightened clinical trial activities and personnel costs.
• General and Administrative Expenses: Rose to $21.2 million from $6.7 million, primarily due to increased personnel and operational costs.
• Cash Position: Ended 2021 with $319.7 million in cash, cash equivalents, and investments, up from $268.2 million in 2020, providing a solid financial foundation for ongoing clinical programs.

2. Strategic Updates and Business Highlights

• Clinical Progress:
  • Completed enrollment for the Phase 2 ACT-AD study and initiated dosing for the Phase 2 study of fosgonimeton (fosgo) in Parkinson's disease dementia.
  • Anticipated top-line data from the ACT-AD study in Q2 2022 and completion of enrollment for the Phase 3 LIFT-AD study by Q3 2022.
  • Positive early results from the Phase 1 study of fosgo published, indicating potential cognitive benefits.
• Board Expansion: Added two new members with extensive experience in CNS drug development to strengthen leadership.
• Diverse Pipeline: Initiated the SHAPE study for Parkinson's disease dementia and advanced ATH-1020, a new compound targeting neurodegenerative diseases.

3. Forward Guidance and Outlook

• Data Expectations: Top-line results from the ACT-AD study are expected in Q2 2022, with insights potentially informing the LIFT-AD study's statistical analysis plan.
• Market Opportunity: The company highlighted the growing prevalence of Alzheimer’s disease, projecting a market of 100 million patients by 2050, emphasizing the need for innovative treatment options.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The significant increase in net loss year-over-year raises concerns about the sustainability of current spending levels without immediate revenue generation.
• Regulatory and Clinical Risks: The success of the ongoing trials is crucial; failure to achieve statistically significant results could impact future funding and development plans.
• Market Competition: The company operates in a highly competitive space with limited approved treatments for Alzheimer’s, underscoring the need for successful differentiation and efficacy.

5. Notable Q&A Insights

• ACT-AD Data Release: Management indicated that while they expect to report primary endpoint results, they may not provide detailed graphs or extensive secondary endpoint data immediately.
• Cognitive Impact Timing: Discussion around the expected timing of cognitive effects indicated that placebo responses could diminish over time, with assessments planned at multiple intervals throughout the trial.
• Enrollment Updates: Management confirmed they are on track to complete enrollment for the LIFT-AD study by the end of Q3 2022 and will announce completion publicly.
• Mechanistic Rationale: The team provided insights into the underlying mechanisms of their therapies, emphasizing the relevance of the HGF/MET system across different neurodegenerative conditions.

Overall, Athira Pharma is positioned for a pivotal year with significant clinical milestones ahead, though it faces challenges related to financial sustainability and competitive pressures in the neurodegenerative disease market.